ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • polymyositis/dermatomyositis (PM/DM) and population studies
  • polymyositis/dermatomyositis (PM/DM) and prednisolone
  • Polymyositis/dermatomyositis (PM/DM) and pregnancy
  • polymyositis/dermatomyositis (PM/DM) and prognostic factors
  • Polymyositis/dermatomyositis (PM/DM) and pulmonary complications
  • polymyositis/dermatomyositis (PM/DM) and quality of life
  • polymyositis/dermatomyositis (PM/DM) and regeneration
  • polymyositis/dermatomyositis (PM/DM) and remission
  • polymyositis/dermatomyositis (PM/DM) and risk assessment
  • polymyositis/dermatomyositis (PM/DM) and rituximab
  • polymyositis/dermatomyositis (PM/DM) and synthetase syndrome
  • polymyositis/dermatomyositis (PM/DM) and treatment
  • polymyositis/dermatomyositis (PM/DM) and ultrasonography
  • polyoma
  • polypharmacy
  • Population medicine
  • Population pharmacokinetics
  • population studies
  • population studies and disability
  • population studies and Health Care
  • population studies and Industry
  • population studies and phenotypes
  • population studies and pregnancy
  • population studies and prevention
  • population studies and prognostic factors
  • population studies and psoriatic arthritis
  • population studies and quality improvement
  • population studies and quality of life
  • population studies and renal disease
  • population studies and rheumatic disease
  • population studies and rheumatoid arthritis (RA)
  • population studies and risk
  • population studies and risk assessment
  • Population studies and sarcoidosis
  • population studies and scleroderma
  • population studies and sleep apnea
  • population studies and socioeconomic factors
  • population studies and spondylarthritis
  • population studies and systemic lupus erythematosus (SLE)
  • population studies and systemic sclerosis
  • population studies and uric acid
  • population studies and utilization review
  • population studies and vaccines
  • population studies and vasculitis
  • population-based
  • Population-based study
  • positron emission tomography
  • positron emission tomography (PET)
  • positron emission tomography (PET) and cardiovascular disease
  • positron emission tomography (PET) and rheumatoid arthritis
  • positron emission tomography (PET) and rheumatoid arthritis (RA)
  • positron emission tomography (PET) and steroids
  • positron emission tomography (PET) and synovitis
  • positron emission tomography (PET) and systemic sclerosis
  • positron emission tomography (PET) and takayasu arteritis
  • positron emission tomography (PET) and treatment
  • positron emission tomography (PET) and ultrasonography
  • positron emission tomography (PET) and ultrasound
  • positron emission tomography (PET) and vasculitis
  • post inflammatory
  • post-translational modification
  • post-translational modification and rheumatoid arthritis (RA)
  • post-translational modification and signal transduction
  • post-traumatic OA
  • Post-Traumatic Osteoarthritis
  • post-traumatic stress disorder
  • posterior reversible encephalopathy syndrome and systemic lupus erythematosus (SLE)
  • poverty
  • poverty and quality of life
  • poverty and race/ethnicity
  • poverty and rheumatoid arthritis (RA)
  • poverty and slicc damage index
  • poverty and socio-economic inequities
  • poverty and systemic lupus erythematosus (SLE)
  • power and quality of life
  • power Doppler
  • PPAR and Pulmonary hypertension
  • PPAR-gamma
  • PQRS
  • pQTL
  • Practice
  • Practice and osteoarthritis
  • Practice and quality of care
  • Practice and rheumatoid arthritis (RA)
  • Practice and ultrasound
  • practice guidelines
  • practice guidelines and immunosuppressants
  • practice guidelines and quality of care
  • practice guidelines and rheumatologic practice
  • practice guidelines and serologic tests
  • practice improvement
  • practice improvement and quality improvement
  • practice improvement and rheumatoid arthritis
  • practice improvement and rheumatoid arthritis (RA)
  • practice improvement and rheumatologic practice
  • practice improvement and spondylarthropathy
  • Practice Management
  • Practice Management and pediatric rheumatology
  • practice patterns
  • Pre existing autoimmune conditions and Immune related adverse events
  • Pre-test probability
  • preclinical RA
  • Preclinical Rheumatoid Arthritis
  • predicting evolution
  • PREDICTION
  • prediction and natural history
  • prediction and screening
  • prediction models
  • PREDICTOR
  • predictors
  • prednisolone
  • prednisone
  • prednisone and methotrexate (MTX)
  • prednisone and pregnancy
  • prednisone and prognostic factors
  • prednisone and rheumatoid arthritis
  • prednisone and rheumatoid arthritis (RA)
  • prednisone and steroids
  • prednisone and temporal arteritis
  • prednisone and temporal artery biopsy
  • prednisone and thrombosis
  • prednisone and tocilizumab
  • prednisone and treatment
  • prednisone and treatment options
  • prednisone and vasculitis
  • Preeclampsia
  • Pregabalin
  • pregnancy
  • pregnancy and biologic drugs
  • pregnancy and cyclophosphamide
  • pregnancy and digital technologies
  • pregnancy and Electronic Health Record
  • pregnancy and epidemiologic methods
  • pregnancy and fertility
  • pregnancy and Gene Expression
  • pregnancy and longitudinal studies
  • pregnancy and meta-analysis
  • pregnancy and practice improvement
  • pregnancy and pregnancy complications
  • pregnancy and prescribing trends
  • Pregnancy and psoriasis
  • pregnancy and psoriatic arthritis
  • pregnancy and qualitative
  • pregnancy and questionnaires
  • pregnancy and registries
  • pregnancy and registry
  • pregnancy and Reproductive Health
  • pregnancy and rheumatic disease
  • pregnancy and rheumatoid arthritis
  • pregnancy and rheumatoid arthritis (RA)
  • pregnancy and ribonucleoprotein (RNP)
  • pregnancy and safety
  • pregnancy and sarcoidosis
  • pregnancy and surgery
  • Pregnancy and systemic lupus erythematosus
  • pregnancy and systemic lupus erythematosus (SLE)
  • Pregnancy and systemic sclerosis
  • Pregnancy and takayasu arteritis
  • pregnancy and thrombosis
  • pregnancy and total joint replacement
  • pregnancy and treatment
  • pregnancy and treatment options
  • Pregnancy and vasculitis
  • pregnancy and vasculogenesis
  • pregnancy and women's health
  • Pregnancy Experiences
  • pregnancy morbidity and Global Anti-Phospholipid Syndrome Score
  • prehabilitation
  • Premature mortality
  • Preoperative
  • Preoperative and osteoarthritis
  • prescribing trends
  • prescribing trends and epidemiologic methods
  • prescribing trends and rheumatoid arthritis (RA)
  • prescribing trends and systemic lupus erythematosus (SLE)
  • prescribing trends and treatment
  • prescribing trends and uric acid
  • Presenteeism
  • Pressure algorimetry and Summated pain level
  • Prevalence
  • prevalence and cytoplasmic
  • prevalence and inflammation
  • prevention
  • prevention and cardiovascular disease
  • prevention and healthcare system
  • prevention and mental health
  • prevention and quality improvement
  • prevention and quality measures
  • prevention and quality of life
  • prevention and radiography
  • prevention and randomized trials
  • prevention and rheumatoid arthritis (RA)
  • prevention and shared dicision making
  • prevention and steroids
  • prevention and systemic lupus erythematosus (SLE)
  • prevention and systemic sclerosis
  • prevention and thrombosis
  • prevention and trauma
  • prevention and treatment
  • prevention and tuberculosis
  • First |
  • « Previous Page
  • 46
  • 47
  • 48
  • 49
  • 50
  • [51]
  • 52
  • 53
  • 54
  • 55
  • 56
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology